Recent advances in the development of breast cancer vaccines

References

• WinkfieldKMHarrisJREffective local therapy and long-term survival in breast cancerOncology200923866967519711579
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• MilesDRochéHMartinMPhase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancerOncologist20111681092110021572124
   PubMed Web of Science ®Google Scholar
• EmensLABreast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockadeExpert Rev Anticancer Ther201212121597161123253225
   PubMed Web of Science ®Google Scholar
• BurnetFMImmunological aspects of malignant diseaseLancet196717501117111744165129
   PubMed Web of Science ®Google Scholar
• ShankaranVIkedaHBruceATIFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature200141068321107111111323675
   PubMed Web of Science ®Google Scholar
• AndersonKSTumor vaccines for breast cancerCancer Invest200927436136819358018
   PubMed Web of Science ®Google Scholar
• WilcoxRATamadaKFliesDBLigation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivoBlood2004103117718412969968
   PubMed Web of Science ®Google Scholar
• HakanssonAGustafssonBKrysanderLHakanssonLTumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatmentBr J Cancer19967456706768845294
   PubMed Web of Science ®Google Scholar
• YasumotoKTakeoSYanoTRole of tumor-infiltrating lymphocytes in the host defense mechanism against lung cancerJ Surg Oncol19883842212262842545
   PubMed Web of Science ®Google Scholar
• RaviRFuchsEJJainAResistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signalingCancer Res20066631730173916452233
   PubMed Web of Science ®Google Scholar
• ZouWImmunosuppressive networks in the tumour environment and their therapeutic relevanceNat Rev Cancer20055426327415776005
   PubMed Web of Science ®Google Scholar
• MuschenMMoersCWarskulatUEvenJNiederacherDBeckmannMWCD95 ligand expression as a mechanism of immune escape in breast cancerImmunology2000991697710651943
   PubMed Web of Science ®Google Scholar
• WolfAMWolfDSteurerMGastlGGunsiliusEGrubeck-LoebensteinBIncrease of regulatory T-cells in the peripheral blood of cancer patientsClin Cancer Res20039260661212576425
   PubMed Web of Science ®Google Scholar
• RikerACormierJPanelliMImmune selection after antigen-specific immunotherapy of melanomaSurgery1999126211212010455872
   PubMed Web of Science ®Google Scholar
• MarchiniCKalogrisCGarulliCTailoring DNA vaccines: designing strategies against HER2-positive cancersFront Oncol2013312223675574
   PubMedGoogle Scholar
• DisisMLCalenoffEMcLaughlinGExistent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancerCancer Res199454116207505195
   PubMed Web of Science ®Google Scholar
• DisisMLPupaSMGralowJRDittadiRMenardSCheeverMAHigh-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancerJ Clin Oncol19971511336333679363867
   PubMed Web of Science ®Google Scholar
• MilesDPapazisisKRationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancerClin Breast Cancer20033Suppl 4S134S13812620150
   PubMedGoogle Scholar
• HsiehCSLeeHMLioCWSelection of regulatory T cells in the thymusNat Rev Immunol201212315716722322317
   PubMed Web of Science ®Google Scholar
• CuriglianoGCriscitielloCEspositoADeveloping an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibriumBreast201322Suppl 2S96S9924074802
   PubMed Web of Science ®Google Scholar
• PenwellASharpKMansourMSammaturLDevelopment and validation of an HPLC/UV assay for separation and quantification of peptide antigens from a liposomal vaccine delivery platformJ Pharm Biomed Anal20126617618222516680
   PubMed Web of Science ®Google Scholar
• MarracheSTundupSHarnDADharSEx vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapyACS Nano2013787392740223899410
   PubMed Web of Science ®Google Scholar
• PouyanfardSBamdadTHashemiHBandehpourMKazemiBInduction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticlesPLoS One2012711e4953923166703
   PubMed Web of Science ®Google Scholar
• KnutsonKLSchiffmanKCheeverMADisisMLImmunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityClin Cancer Res2002851014101812006513
   PubMed Web of Science ®Google Scholar
• KnutsonKLSchiffmanKDisisMLImmunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patientsJ Clin Invest2001107447748411181647
   PubMed Web of Science ®Google Scholar
• ZaksTZRosenbergSAImmunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumorsCancer Res19985821490249089809997
   PubMed Web of Science ®Google Scholar
• MittendorfEAHolmesJPMurrayJLvon HofeEPeoplesGECD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)Expert Opin Biol Ther200991717819063694
   PubMed Web of Science ®Google Scholar
• PardollDMTopalianSLThe role of CD4+ T cell responses in antitumor immunityCurr Opin Immunol19981055885949794842
   PubMed Web of Science ®Google Scholar
• ZwavelingSFerreira MotaSCNoutaJEstablished human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptidesJ Immunol2002169135035812077264
   PubMed Web of Science ®Google Scholar
• MilaniASangioloDMontemurroFAgliettaMValabregaGActive immunotherapy in HER2 overexpressing breast cancer: current status and future perspectivesAnn Oncol20132471740174823585514
   PubMed Web of Science ®Google Scholar
• GalloPDharmapuriSNuzzoMXenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vectorInt J Cancer20051131677715386429
   PubMed Web of Science ®Google Scholar
• Prud’hommeGJDNA vaccination against tumorsJ Gene Med20057131715538731
   PubMed Web of Science ®Google Scholar
• HuiKMAngPTHuangLTaySKPhase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexesGene Ther1997487837909338006
   PubMed Web of Science ®Google Scholar
• PecherGSpahnGSchirrmannTMucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirusAnticancer Res2001214A2591259611724326
   PubMed Web of Science ®Google Scholar
• LiuZLvDLiuSAlginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in micePLoS One201384e6019023577091
   PubMed Web of Science ®Google Scholar
• CurcioCDi CarloEClynesRNonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomasJ Clin Invest200311181161117012697735
   PubMed Web of Science ®Google Scholar
• SpadaroMAmbrosinoEIezziMCure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunityClin Cancer Res20051151941195215756020
   PubMed Web of Science ®Google Scholar
• RohrbachFWethRKursarMSlootsAMittruckerHWWelsWSTargeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunityJ Immunol200517495481548915843546
   PubMed Web of Science ®Google Scholar
• NabekuraTNagasawaTNakauchiHOnoderaMAn immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2Cancer Immunol Immunother200857561162217786440
   PubMed Web of Science ®Google Scholar
• ZhangYMaBZhouYDendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cellsBreast Cancer Res Treat2007105327728617187233
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• SmallEJSchellhammerPFHiganoCSPlacebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerJ Clin Oncol200624193089309416809734
   PubMed Web of Science ®Google Scholar
• RossiGRMautinoMRAwwadDZAllogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicityJ Immunother200831654555418528300
   PubMed Web of Science ®Google Scholar
• KeenanBPJaffeeEMWhole cell vaccines – past progress and future strategiesSemin Oncol201239327628622595050
   PubMed Web of Science ®Google Scholar
• CuriglianoGSpitaleriGPietriEBreast cancer vaccines: a clinical reality or fairy tale?Ann Oncol200617575076216293674
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• BaselgaJCortesJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• AwadaADirixLManso SanchezLSafety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapyAnn Oncol201324110911622967996
   PubMed Web of Science ®Google Scholar
• GeunaEMontemurroFAgliettaMValabregaGPotential of afatinib in the treatment of patients with HER2-positive breast cancerBreast Cancer2012413113724367201
   PubMedGoogle Scholar
• PeoplesGEGoedegebuurePSSmithRLinehanDCYoshinoIEberleinTJBreast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptideProc Natl Acad Sci USA19959224324367831305
   PubMed Web of Science ®Google Scholar
• FiskBBlevinsTLWhartonJTIoannidesCGIdentification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte linesJ Exp Med19951816210921177539040
   PubMed Web of Science ®Google Scholar
• DisisMLGooleyTARinnKGeneration of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccinesJ Clin Oncol200220112624263212039923
   PubMed Web of Science ®Google Scholar
• MurrayJLGilloglyMEPrzepiorkaDToxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancerClin Cancer Res20028113407341812429628
   PubMed Web of Science ®Google Scholar
• SalazarLGGoodellVO’MearaMPersistent immunity and survival after immunization with a HER2/neu (HER2) vaccineASCO Meeting Abstracts2009Orlando, FL
   Google Scholar
• PeoplesGEGurneyJMHuemanMTClinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patientsJ Clin Oncol200523307536754516157940
   PubMed Web of Science ®Google Scholar
• PeoplesGEHolmesJPHuemanMTCombined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clin Cancer Res200814379780318245541
   PubMed Web of Science ®Google Scholar
• MittendorfEACliftonGTHolmesJPFinal report of the Phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patientsAnnals of Oncology20142591735174224907636
   PubMed Web of Science ®Google Scholar
• AminABenavidesLCHolmesJPAssessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Cancer Immunol Immunother200857121817182518392824
   PubMed Web of Science ®Google Scholar
• BenavidesLCGatesJDCarmichaelMGThe impact of HER2/neu expression level on response to the E75 vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clin Cancer Res20091582895290419351776
   PubMed Web of Science ®Google Scholar
• MittendorfEACliftonGTHolmesJPClinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Cancer2012118102594260221989902
   PubMed Web of Science ®Google Scholar
• HolmesJPBenavidesLCGatesJDResults of the first Phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJ Clin Oncol200826203426343318612158
   PubMed Web of Science ®Google Scholar
• HaleDFPerezSAVreelandTJAn assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized Phase II trialASCO Meeting Abstracts2012Chicago, IL
   Google Scholar
• AnastasopoulouEAPappouETzonisPBooster inoculations of the AE37 peptide vaccine enhance immunological responses in a Phase II studyASCO Meeting Abstracts201331Suppl 153095
   Google Scholar
• CarmichaelMGBenavidesLCHolmesJPResults of the first Phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04Cancer2010116229230119924797
   PubMed Web of Science ®Google Scholar
• TrappeyFBerryJSVreelandTJRandomized Phase II clinical trial of the anti-HER2 (GP2) vaccine to prevent recurrence in high-risk breast cancer patients: a planned interim analysisASCO Meeting Abstracts201331Suppl 153005
   Google Scholar
• DisisMLSchiffmanKGuthrieKEffect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein – based vaccineJ Clin Oncol200422101916192515143085
   PubMed Web of Science ®Google Scholar
• GuardinoACassidyMPienkowskiTResults of two Phase I clinical trials of MVA-BN(R)-HER2 in HER-2 overexpressing metastatic breast cancer patientsCancer Res200969245089
   Web of Science ®Google Scholar
• LimentaniSDorvalTWhiteSPhase I dose-escalation trial of a recombinant HER2 vaccine in patients with stage II/III HER2+ breast cancerASCO Meeting Abstracts2005Chicago, IL
   Google Scholar
• EmensLAAsquithJMLeathermanJMTimed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationJ Clin Oncol200927355911591819805669
   PubMed Web of Science ®Google Scholar
• YangEHuXFXingPXAdvances of MUC1 as a target for breast cancer immunotherapyHistol Histopathol200722890592217503348
   PubMed Web of Science ®Google Scholar
• TarpMAClausenHMucin-type O-glycosylation and its potential use in drug and vaccine developmentBiochim Biophys Acta20081780354656317988798
   PubMed Web of Science ®Google Scholar
• ApostolopoulosVXingPXMcKenzieIFMurine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigensCancer Res19945419518651937923138
   PubMed Web of Science ®Google Scholar
• ZhangSGraeberLAHellingFAugmenting the immunogenicity of synthetic MUC1 peptide vaccines in miceCancer Res19965614331533198764127
   PubMed Web of Science ®Google Scholar
• AcresRBHareuveniMBalloulJMKienyMPVaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigenJ Immunother Emphasis Tumor Immunol19931421361438280702
   PubMed Web of Science ®Google Scholar
• GoydosJSElderEWhitesideTLFinnOJLotzeMTA Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinomaJ Surg Res19966312983048667619
   PubMed Web of Science ®Google Scholar
• RamanathanRKLeeKMMcKolanisJPhase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancerCancer Immunol Immunother200554325426415372205
   PubMed Web of Science ®Google Scholar
• AdluriSGilewskiTZhangSRamnathVRagupathiGLivingstonPSpecificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21Br J Cancer19997911–121806181210206297
   PubMed Web of Science ®Google Scholar
• GilewskiTAdluriSRagupathiGVaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21Clin Cancer Res2000651693170110815887
   PubMed Web of Science ®Google Scholar
• PalmerMParkerJModiSPhase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancerClin Lung Cancer2001314957 discussion 5814656392
   PubMedGoogle Scholar
• MacLeanGDReddishMKogantyRRImmunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvantCancer Immunol Immunother19933642152228439984
   PubMed Web of Science ®Google Scholar
• ReddishMAMacLeanGDPoppemaSBergALongeneckerBMPre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapyCancer Immunol Immunother19964253033098706053
   PubMed Web of Science ®Google Scholar
• MilesDWTowlsonKEGrahamRA randomised Phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancerBr J Cancer1996748129212968883420
   PubMed Web of Science ®Google Scholar
• XingPMichaelMApostolopoulosVPhase-I study of synthetic muc1 peptides in breast-cancerInt J Oncol1995661283128921556671
   PubMed Web of Science ®Google Scholar
• KaranikasVHwangLAPearsonJAntibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion proteinJ Clin Invest199710011278327929389743
   PubMed Web of Science ®Google Scholar
• KaranikasVLoddingJMainoVCMcKenzieIFFlow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapyClin Cancer Res20006382983710741704
   PubMed Web of Science ®Google Scholar
• KaranikasVThynneGMitchellPMannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injectionJ Immunother2001242172183
   Web of Science ®Google Scholar
• ApostolopoulosVPieterszGATsibanisAPilot Phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]Breast Cancer Res200683R2716776849
   PubMed Web of Science ®Google Scholar
• VassilarosSTsibanisATsikkinisAPieterszGAMcKenzieIFApostolopoulosVUp to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1Immunotherapy20135111177118224188672
   PubMed Web of Science ®Google Scholar
• TurrizianiMFantiniMBenvenutoMCarcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trialsRecent Pat Anticancer Drug Discov20127326529622630596
   PubMed Web of Science ®Google Scholar
• CuriglianoGRescignoMGoldhirschAImmunology and breast cancer: therapeutic cancer vaccinesBreast200716Suppl 2S20S2617706425
   PubMed Web of Science ®Google Scholar
• MadanRAArlenPMGulleyJLPANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinomaExpert Opin Biol Ther20077454355417373905
   PubMed Web of Science ®Google Scholar
• MohebtashMTsangKYMadanRAA pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancerClin Cancer Res201117227164717322068656
   PubMed Web of Science ®Google Scholar
• GulleyJLArlenPMTsangKYPilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaClin Cancer Res200814103060306918483372
   PubMed Web of Science ®Google Scholar
• CovelerALBatesNEDisisMLProgress in the development of a therapeutic vaccine for breast cancerBreast Cancer20102253624367164
   PubMedGoogle Scholar
• VonderheideRHDomchekSMSchultzeJLVaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytesClin Cancer Res200410382883914871958
   PubMed Web of Science ®Google Scholar
• DomchekSMRecioAMickRTelomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillanceCancer Res20076721105461055517974999
   PubMed Web of Science ®Google Scholar
• DisisMLWallaceDRGooleyTAConcurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerJ Clin Oncol200927284685469219720923
   PubMed Web of Science ®Google Scholar
• PatilRCliftonGTLittonJKSafety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant settingASCO Meeting Abstracts201331Suppl 153096
   Google Scholar
• EmensLAGuptaRPetrikSA feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancerASCO Meeting Abstracts2011Chicago, IL
   Google Scholar
• NorellHPoschkeICharoJVaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialJ Transl Med201085320529245
   PubMed Web of Science ®Google Scholar
• HamiltonEBlackwellKHobeikaACPhase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibitionJ Transl Med2012102822325452
   PubMed Web of Science ®Google Scholar